Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GE Vernova Inc (GEV) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

GE Vernova IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs GE Vernova Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while GE Vernova Inc trades at $1,043.8 (market cap $269.50B). The key difference: GE Vernova Inc is far larger — about 9.1× Alnylam Pharmaceuticals, Inc.'s market cap, and GE Vernova Inc pays a 0.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

	ALNY	GEV
Market Cap	$29.60B	$269.50B
Sector	Health	Technology
52-Week High	$491.22	$1.17K
52-Week Low	$205.48	$547.96
Enterprise Value	$27.56B	$259.17B
Dividend Yield	—	0.2%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

GE Vernova Inc

GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.

Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ALNY

View details →

GEV

GE Vernova set for strong growth with $46B revenue forecast by 2026, driven by AI and data center demandSeeking Alpha · 4 hours agoBullish GE Vernova upgraded to buy on strong guidance, backlog, and growth potential despite high valuation risksSeeking Alpha · 11 hours agoBullish GE Vernova benefits from AI-driven power and grid bottlenecks but faces high expectations at 28x 2028 earnings.Seeking Alpha · 19 hours agoNeutral View details →

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.